Opdualag (Nivolumab and Relatlimab-Rmbw) for Melanoma

Overview
Opdualag is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults and children 12 years of age or older with melanoma that has spread or cannot be removed by surgery. It’s also known by its drug name, nivolumab and relatlimab-rmbw.

This medication combines two antibodies: the lymphocyte activation gene (LAG)-3-blocking antibody relatlimab and the programmed death receptor (PD)-1 blocking antibody nivolumab. These antibodies work together to enhance the body’s immune response against melanoma cells​​​​. 

How do I take it?
Opdualag is administered through an intravenous (IV) infusion, delivered directly into the bloodstream by a health care professional. The dosage is usually given every four weeks. The duration of the treatment and the number of infusions depend on the individual’s response to the medication and any side effects experienced​​.

Side effects
Common side effects include fatigue, rash, itching, diarrhea, joint and muscle pain, and changes in liver function and blood tests. Infusion reactions, including symptoms like fever or chills, rash, shortness of breath, and back pain, are also possible. 

Serious side effects may include lung problems (such as new or worsening cough, shortness of breath, and chest pain), intestinal issues (like diarrhea or severe abdominal pain), liver problems (including yellowing of the skin or eyes), hormonal gland issues (such as headaches, rapid heartbeat, and extreme tiredness), kidney problems, skin issues (severe rash or blistering), and inflammation-related heart problems (chest pain, shortness of breath, irregular heartbeat).

For more details about this treatment, visit:

Opdualag — Nivolumab and Relatlimab-Rmbw Injection — DailyMed